Clinical Application of CAR T Cells 2019
Mar 14, 2019 8:00 AM
Chimeric antigen receptor (CAR) T-cell ("Living Drug") immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more are on track to be initiated next year. Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside and back to bench – constructing, manufacturing and obtaining FDA approvals for clinical grade CARs and vectors, developing universal algorithms across multiple CAR T-cell clinical trials for the treatment and management of complications, and conducting world-class correlative science.
MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact email@example.com for more information.
Read more and register here